Related Experiment Video
Updated: May 24, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
[Clinical and genetic aspects of hypertrophic and dilated cardiomyopathy]
1Abteilung Innere Medizin III (Schwerpunkt Kardiologie, Angiologie und Pneumologie), Universitätsklinikum Heidelberg.
Insights
Primary cardiomyopathies affect 0.3-0.4% of people, causing heart failure and sudden death. Genetic testing and family screening improve diagnosis and risk assessment for these heart muscle diseases.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Context:
- Primary cardiomyopathies are prevalent heart conditions affecting 0.3-0.4% of the population.
- These diseases are a major cause of heart failure and sudden cardiac death in young individuals.
- Genetic factors play a significant role, with 49 identified disease genes linked to hypertrophic and dilated cardiomyopathy.
Purpose:
- To highlight the importance of molecular genetic studies in understanding cardiomyopathies.
- To emphasize the role of next-generation sequencing in efficiently screening disease genes.
- To underscore the necessity of family investigations for identifying affected and asymptomatic mutation carriers.
Summary:
- Next-generation sequencing enables comprehensive screening of known cardiomyopathy genes.
- Identifying specific genotypes aids in diagnostic classification.
- Family screening is crucial for detecting familial aggregation and carriers.
- Genotype detection improves risk stratification for patients with cardiomyopathies.
Impact:
- Enhanced diagnostic accuracy for primary cardiomyopathies.
- Improved risk stratification and personalized management strategies.
- Facilitation of early detection and intervention in affected families.
- Advancement of genetic understanding of heart muscle diseases.
Abstract:
Primary cardiomyopathies are frequent heart diseases with an estimated prevalence of 0.3-0.4% in the general population, significantly contributing to systolic heart failure and sudden cardiac death in the young. Molecular genetic studies have identified 49 different disease genes for hypertrophic and dilated cardiomyopathy, often involving proteins of the sarcomere, the cardiac Z-disc and the cytoskeleton. With the development of new, advanced technologies based on next-generation sequencing, it is now possible to efficiently screen all known disease genes in an individual patient. The clinical workup of cardiomyopathies should always include the investigation of the patient's family to account for the familial aggregation of cardiomyopathies and identify diseased as well as asymptomatic carriers of mutations. The detection of specific genotypes facilitates diagnostic classification and can improve risk stratification in affected patients.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy V: Interprofessional Care
Heart Failure II: Pathophysiology
Cardiomyopathy IV: Restrictive Cardiomyopathy

